Measurement error in the timing of events: Effect on survival analyses in randomized clinical trials

Clinical Trials

Volumn 7, Issue 6, 2010, Pages 626-633

  Korn, Edward L ^a   Dodd, Lori E ^b   Freidlin, Boris ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); HAZARD RATIO; MEASUREMENT ERROR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION;

ANTIBODIES, MONOCLONAL; BIAS (EPIDEMIOLOGY); DISEASE PROGRESSION; FACTOR ANALYSIS, STATISTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78650359532     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510382801     Document Type: Article

References (16)

1. Goldberg P. Avastin vote puts focus on FDA criteria in first-line metastatic breast cancer. Cancer Lett 2007 ; 33: 1-6 (14 December 2007 ).
2. Anonymous. PFS is a benefit 'In the Right Context,' Pazdur says in Q&A on Avastin approval. Cancer Lett 2008 ; 34: 1-4 (29 February 2008 ).
3. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 ; 357: 2666-76.
4. Gray R., Bhattacharya S., Bowden C., et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009 ; 27: 4966-72.
5. FDA. FDA briefing document, Oncologic Drugs Advisory Committee Meeting, December 5, 2007. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/ 2007-4332b1-00-index.htm (accessed 18 August 2010 ).
6. FDA. Transcript of the FDA presentation to the December 5, 2007 Oncologic Drugs Advisory Committee Meeting. Available at: http://www.fda.gov/OHRMS/ DOCKETS/AC/cder07.htm#OncologicDrugs (accessed 18 August 2010 ).
7. Carroll KJ Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 2007 ; 6: 99-113.
8. Williams G., He K., Chen G., et al. Operational bias in assessing time to progression (TTP). Proc Am Soc Clin Oncol 2002 ; 20: 244 (abstr 975).
9. Pangeas KS, Ben-Porat L., Dickler MN, et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007 ; 99: 428-32.
10. Bhattacharya S., Fyfe G., Gray RJ, Sargent DJ Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol 2009 ; 27: 5958-64.
11. Freidlin B., Korn EL, Hunsberger S., et al. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007 ; 25: 2122-26.
12. Carroll RJ Measurement error in epidemiologic studies. In Armitage P, Colton T. (eds). Encyclopedia of Biostatistics. John Wiley, New York, 1998, pp. 2491-519.
13. Rubinstein LV, Gail MH, Santner TJ Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observations. J Chronic Dis 1981 ; 34: 469-79.
14. Dodd LE, Korn EL, Freidlin B., et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 2008 ; 22: 3791-96.
15. Meier AS, Richardson BA, Hughes JP Discrete proportional hazards models for mismeasured outcomes. Biometrics 2003 ; 59: 947-54.
16. Skinner CJ, Humphreys K. Weibull regression for lifetimes measured with error. Lifetime Data Anal 1999 ; 5: 23-37.